Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 ROUNDTABLE DISCUSSION
read more
Podcasts
CHICAGO 2022 BREAST ROUNDTABLE DISCUSSION
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 BREAST ROUNDTABLE DISCUSSION: T-DXd Versus Treatment of TPC in Patients with HER2-Low Unresectable and/or mBC: Results of DESTINY-Breast04
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 BREAST ROUNDTABLE DISCUSSION: Analyses From PALOMA-2
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 BREAST ROUNDTABLE DISCUSSION: Primary Results From TROPiCS-02
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 BREAST ROUNDTABLE DISCUSSION: Results From the Phase 1/2 Study of Patritumab Deruxtecan, a HER3-Directed ADC, in Patients with HER3-Expressing MBC.
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 BREAST ROUNDTABLE DISCUSSION: Phase 1b/2 Study of BCL-2 Inhibitor Lisaftoclax Safety and Tolerabolity when Administered in Patients with ER+BC or Advanced Solid Tumors.
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 BREAST ROUNDTABLE DISCUSSION: FAKTION
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 BREAST ROUNDTABLE DISCUSSION: NRG-BR002
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 GI ROUNDTABLE DISCUSSION
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 GI ROUNDTABLE DISCUSSION: Gastrointestinal Cancer — Colorectal
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 GI ROUNDTABLE DISCUSSION: Gastrointestinal Cancer — Pancreatic
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 GU ROUNDTABLE DISCUSSION
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 GU ROUNDTABLE DISCUSSION: Prostate Cancer Abstracts
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 GU ROUNDTABLE DISCUSSION: Renal Cell Carcinoma Abstracts
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 GU ROUNDTABLE DISCUSSION: Urothelial Cancer Abstracts
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 LUNG ROUNDTABLE DISCUSSION
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 LUNG ROUNDTABLE DISCUSSION: Metastatic NSCLC
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 LUNG ROUNDTABLE DISCUSSION: Early Stage NSCLC
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 LUNG ROUNDTABLE DISCUSSION: Small Cell Lung Cancer Extensive Stage First and Second Line
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 MELANOMA ROUNDTABLE DISCUSSION
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 MELANOMA ROUNDTABLE DISCUSSION: KEYNOTE 716
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 MELANOMA ROUNDTABLE DISCUSSION: PRADO
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 MELANOMA ROUNDTABLE DISCUSSION: RELATIVITY 047
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 MELANOMA ROUNDTABLE DISCUSSION: DREAMseq Phase III Trial
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 MELANOMA ROUNDTABLE DISCUSSION: Nevtemadlin Activity After Failure of Anti-PD1/L1 Therapy in Patients with TP53WT Merkel Cell Cancer
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 MELANOMA ROUNDTABLE DISCUSSION: Nivolumab + Tacrolimus + Prednisone +- IPI for Kidney Transplant Recipients
Learning Objectives: Lorem ipsum dolor sit amet,...
CHICAGO 2022 MELANOMA ROUNDTABLE DISCUSSION: The Phase II Clinical Trial of First Line Therapy for Patients with Advanced Acral Melanoma
Learning Objectives: Lorem ipsum dolor sit amet,...
EHA 2022 ROUNDTABLE DISCUSSIONS
Learning Objectives: Lorem ipsum dolor sit amet,...
EHA 2022 LEUKEMIA ROUNDTABLE DISCUSSION
Learning Objectives: Lorem ipsum dolor sit amet,...
EHA 2022 LEUKEMIA ROUNDTABLE DISCUSSION: CML
Learning Objectives: Lorem ipsum dolor sit amet,...
EHA 2022 LEUKEMIA ROUNDTABLE DISCUSSION: ALL
Learning Objectives: Lorem ipsum dolor sit amet,...
EHA 2022 LEUKEMIA ROUNDTABLE DISCUSSION: AML
Learning Objectives: Lorem ipsum dolor sit amet,...
EHA 2022 LYMPHOMA ROUNDTABLE DISCUSSION
Learning Objectives: Lorem ipsum dolor sit amet,...
EHA 2022 LYMPHOMA ROUNDTABLE DISCUSSION: Gene Therapy, Cellular Immunotherapy and Vaccination
Learning Objectives: Lorem ipsum dolor sit amet,...
EHA 2022 LYMPHOMA ROUNDTABLE DISCUSSION: Hodgkin Lymphoma
Learning Objectives: Lorem ipsum dolor sit amet,...
EHA 2022 LYMPHOMA ROUNDTABLE DISCUSSION: Indolent & Mantle Cell NHL
Learning Objectives: Lorem ipsum dolor sit amet,...
EHA 2022 LYMPHOMA ROUNDTABLE DISCUSSION: CLL
Learning Objectives: Lorem ipsum dolor sit amet,...
EHA 2022 MULTIPLE MYELOMA ROUNDTABLE DISCUSSION
Learning Objectives: Lorem ipsum dolor sit amet,...
EHA 2022 MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: Initial Therapy
Learning Objectives: Lorem ipsum dolor sit amet,...
EHA 2022 MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: Early Relapse
Learning Objectives: Lorem ipsum dolor sit amet,...
EHA 2022 MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: New CAR-T Cell Platforms
Learning Objectives: Lorem ipsum dolor sit amet,...
EHA 2022 MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: New Therapeutic Monoclonal Antibody/Combination Therapy
Learning Objectives: Lorem ipsum dolor sit amet,...
EHA 2022 MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: Teclistamab treatment after other BCMA-directed therapy
Learning Objectives: Lorem ipsum dolor sit amet,...
Best of ASCO® Vancouver 2022
Best of ASCO® Vancouver 2022Learning Objectives: 1) To...
Best of ASCO® Vancouver 2022: Bristol Myers Squibb Symposium: Expert Insights on the Evolving Canadian Treatment Landscape in Advanced NSCLC Without Actionable Driver Mutations – Dr. Barbara Melosky & Dr. Cheryl Ho
Learning Objectives: Best of ASCO® Vancouver 2022: Bristol...
Best of ASCO® Vancouver 2022: Non-Prostate GU Cancer – Dr. Christian Kollmannsberger
Learning Objectives: Best of ASCO® Vancouver 2022:...
Best of ASCO® Vancouver 2022: Prostate Cancer – Dr. Kim Chi
Learning Objectives: Best of ASCO® Vancouver 2022:...
Best of ASCO® Vancouver 2022: Non-Colorectal GI Cancer – Dr. Christina Kim
Learning Objectives: Best of ASCO® Vancouver 2022:...
Best of ASCO® Vancouver 2022: Colorectal GI Cancer – Dr. Sharlene Gill
Learning Objectives: Best of ASCO® Vancouver 2022:...
Best of ASCO® Vancouver 2022: Equity in Cancer Care – Dr. Bishal Gyawali
Learning Objectives: Best of ASCO® Vancouver 2022: Equity...
Best of ASCO® Vancouver 2022: Seagen Symposium: CNS Metastases in Breast Cancer: Optimizing Treatment for HER2+ MBC Patients – Dr. Marc Webster & Dr. Jeff Cao
Learning Objectives: Best of ASCO® Vancouver 2022: Seagen...
Best of ASCO® Vancouver 2022: Sarcoma – Dr. Alannah Smrke
Learning Objectives: Best of ASCO® Vancouver 2022:...
Best of ASCO® Vancouver 2022: Lung Cancer – Dr. Aliyah Pabani
Learning Objectives: Best of ASCO® Vancouver 2022: Lung...
Best of ASCO® Vancouver 2022: Breast Cancer – Dr. Nancy Nixon
Learning Objectives: Best of ASCO® Vancouver 2022: Breast...
Best of ASCO® Vancouver 2022: Melanoma – Dr. Jose Monzon
Learning Objectives: Best of ASCO® Vancouver 2022:...
Best of ASCO® Montreal 2022
Best of ASCO® Montreal 2022Learning Objectives: 1) To...
Best of ASCO® Montreal 2022: Gilead Symposium: ADCs in the clinical management of TNBC – Dr. Jean-Pierre Ayoub & Dr. Khashayar Esfahani
Learning Objectives: Best of ASCO® Montreal 2022: Gilead...
Best of ASCO® Montreal 2022: Melanoma – Dr. Wilson Miller
Learning Objectives: Best of ASCO® Montreal 2022:...
Best of ASCO® Montreal 2022: Neoadjuvant Breast Cancer – Dr. Rami Younan
Learning Objectives: Best of ASCO® Montreal 2022:...
Best of ASCO® Montreal 2022: Metastatic Breast Cancer – Dr. Jamil Asselah
Learning Objectives: Best of ASCO® Montreal 2022:...
Best of ASCO® Montreal 2022: GU Updates – Dr. Cristiano Ferrario
Learning Objectives: Best of ASCO® Montreal 2022: GU...
Best of ASCO® Montreal 2022: Lung Cancer – Dr. Elie Kassouf
Learning Objectives: Best of ASCO® Montreal 2022: Lung...
Best of ASCO® Montreal 2022: Colorectal GI Cancer – Dr. Francine Aubin
Learning Objectives: Best of ASCO® Montreal 2022:...
Best of ASCO® Montreal 2022: Non-Colorectal GI Cancer – Dr. Petr Kavan
Learning Objectives: Best of ASCO® Montreal 2022:...
Best of ASCO® Montreal 2022: Practice Changing Data – Dr. Nicholas Meti
Learning Objectives: Best of ASCO® Montreal 2022: Practice...
Best of ASCO® Montreal 2022: Non-Myeloma Hematology – Dr. Olivier Veilleux
Learning Objectives: Best of ASCO® Montreal 2022:...
Best of ASCO® Montreal 2022: Myeloma – Dr. Richard LeBlanc
Learning Objectives: Best of ASCO® Montreal 2022:...
Best of ASCO® Toronto 2022
Best of ASCO Toronto 2022Learning Objectives: 1) To...
Best of ASCO® Toronto 2022: Lung Cancer – Dr. Kirstin Perdrizet
Best of ASCO® Toronto 2022: Lung CancerLearning...
Best of ASCO® Toronto 2022: Canadian Achievements in Cancer Research – Dr. Aynharan Sinnarajah
Best of ASCO® Toronto 2022: Canadian Achievements in...
Best of ASCO® Toronto 2022: Hematology – Dr. Sita Bhella
Learning Objectives: Best of ASCO® Toronto 2022:...
Best of ASCO® Toronto 2022: Non-Colorectal GI Cancer – Dr. Michael Raphael
Best of ASCO® Toronto 2022: Non-Colorectal GI...
Best of ASCO® Toronto 2022: Colorectal GI Cancer – Dr. Stephanie Snow
Best of ASCO® Toronto 2022: Colorectal GI CancerLearning...
Best of ASCO® Toronto 2022: Bristol Myers Squibb Symposium: Expert Insights on the Evolving Canadian Treatment Landscape in Advanced NSCLC – Dr. Rosalyn Juergens & Dr. Adrian Sacher
Best of ASCO® Toronto 2022: Bristol Myers Squibb...
Best of ASCO® Toronto 2022: Melanoma – Dr. Marcus Butler
Best of ASCO® Toronto 2022: MelanomaLearning Objectives:...
Best of ASCO® Toronto 2022: Gynecological Cancer – Dr. Helen MacKay
Best of ASCO® Toronto 2022: Gynecological CancerLearning...
Best of ASCO® Toronto 2022: Breast Cancer – Dr. Dave Cescon
Best of ASCO® Toronto 2022: Breast CancerLearning...
Best of ASCO® Toronto 2022: Non-Prostate GU Cancer – Dr. Srikala Sridhar
Best of ASCO® Toronto 2022: Non-Prostate GU CancerLearning...
Best of ASCO® Toronto 2022: Prostate Cancer – Dr. Sebastien Hotte
Best of ASCO® Toronto 2022: Prostate CancerLearning...
Best of ASCO® Toronto 2022: Gilead Symposium: ADCs in the clinical management of TNBC- Dr. John Hilton & Dr. Christine Brezden-Masley
Best of ASCO® Toronto 2022: Gilead Symposium: ADCs in the...
Physician Burnout in Oncology: The 3Rs – Recognition, Resilience and Relationships: Shifting Culture & Shared Learnings: Building Community to Support Canadian Medical Oncologists
Physician Burnout in Oncology: The 3Rs – Recognition,...
Physician Burnout in Oncology: The 3Rs – Recognition, Resilience and Relationships: Physician Heal Thyself
Physician Burnout in Oncology: The 3Rs – Recognition,...
Physician Burnout in Oncology: The 3Rs – Recognition, Resilience and Relationships
Physician Burnout in Oncology: The 3Rs - Recognition,...
Building Back Better: Oncology in a Post-Pandemic World – An OncologyEducation Symposium in Collaboration with CAMO
Building Back Better: Oncology in a Post-Pandemic World –...
Dose Optimization Strategy of Ponatinib in Patients with CP-CML
Dose Optimization Strategy of Ponatinib in Patients with...
Best of GU & GI Cancers Conference 2022
Learning Objectives: Lorem ipsum dolor sit amet,...
BEST OF GU & GI CANCERS CONFERENCE 2022: Ipsen Breakfast Symposium: 2L RCC- making informed treatment decisions after progression on novel 1L combination treatments – Dr. Aly-Khan Lalani
Learning Objectives: BEST OF GU & GI CANCERS...
BEST OF GU & GI CANCERS CONFERENCE 2022: Case-Based Presentation in GU Cancers – Dr. Maria Jiang
Learning Objectives: BEST OF GU & GI CANCERS...
BEST OF GU & GI CANCERS CONFERENCE 2022: Bladder Cancer – Prof. Thomas Powles
Learning Objectives: BEST OF GU & GI CANCERS...
BEST OF GU & GI CANCERS CONFERENCE 2022: Prostate Cancer – Dr. Sebastien Hotte
Learning Objectives: BEST OF GU & GI CANCERS...
BEST OF GU & GI CANCERS CONFERENCE 2022: Kidney Cancer – Dr. Daniel Heng
Learning Objectives: BEST OF GU & GI CANCERS...
BEST OF GU & GI CANCERS CONFERENCE 2022: Pfizer Lunch Symposium: Using ctDNA to Assess MRD – A promising prognostic marker in Colorectal Cancer – Dr. Arvind Dasari & Dr. Bryan Lo
Learning Objectives: BEST OF GU & GI CANCERS...
BEST OF GU & GI CANCERS CONFERENCE 2022: Colorectal Cancer – Dr. Sharlene Gill
Learning Objectives: BEST OF GU & GI CANCERS...
BEST OF GU & GI CANCERS CONFERENCE 2022: Pancreatic Cancer – Dr. Grainne O’Kane
Learning Objectives: BEST OF GU & GI CANCERS...
BEST OF GU & GI CANCERS CONFERENCE 2022: Gastroesophageal Cancer – Dr. Elena Elimova
Learning Objectives: BEST OF GU & GI CANCERS...
BEST OF GU & GI CANCERS CONFERENCE 2022: Hepatobiliary – Dr. Marina Baretti
Learning Objectives: BEST OF GU & GI CANCERS...
BEST OF GU & GI CANCERS CONFERENCE 2022: Case-Based Presentation in GI Cancers – Dr. Suneil Khanna
Learning Objectives: BEST OF GU & GI CANCERS...
Physician Burnout in Oncology: The 3Rs – Recognition, Resilience and Relationships: Strategies to Reduce Burnout & Support Wellbeing in Oncology
Physician Burnout in Oncology: The 3Rs – Recognition,...
Case Based Discussion: Integration and Optimization of HER2+ MBC Treatment Options
Case Based Discussion: Integration and Optimization of...
Case Based Discussion: Integration and Optimization of HER2+ MBC Treatment Options – Dr. Jan-Willem Henning & Dr. Joyce O’Shaughnessy
Learning Objectives: Case Based Discussion: Integration...
Case Based Discussion: Integration and Optimization of HER2+ MBC Treatment Options – Dr. Katarzyna Jerzak & Dr. Joyce O’Shaughnessy
Learning Objectives: Case Based Discussion: Integration...
Case Based Discussion: Integration and Optimization of HER2+ MBC Treatment Options – Dr. Jean-Pierre Ayoub & Dr. Claudine Isaacs
Learning Objectives: Case Based Discussion: Integration...
ASH 2021 ROUNDTABLE DISCUSSIONS: MULTIPLE MYELOMA
Learning Objectives: ASH 2021 ROUNDTABLE DISCUSSIONS:...
ASH 2021 ROUNDTABLE DISCUSSIONS: MULTIPLE MYELOMA — 3776 Lenalidomide Compared to Ixazomib Maintenance in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
ASH 2021 ROUNDTABLE DISCUSSIONS: MULTIPLE MYELOMA — 3776...
ASH 2021 ROUNDTABLE DISCUSSIONS: MULTIPLE MYELOMA — 329 Normalization of the Immune Microenvironment during Lenalidomide Maintenance Is Associated with Sustained MRD Negativity in Patients with Multiple Myeloma
ASH 2021 ROUNDTABLE DISCUSSIONS: MULTIPLE MYELOMA — 329...
ASH 2021 ROUNDTABLE DISCUSSIONS: MULTIPLE MYELOMA — 899 Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)
ASH 2021 ROUNDTABLE DISCUSSIONS: MULTIPLE MYELOMA — 899...
ASH 2021 ROUNDTABLE DISCUSSIONS: MULTIPLE MYELOMA — 820 Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment
ASH 2021 ROUNDTABLE DISCUSSIONS: MULTIPLE MYELOMA — 820...
ASH 2021 ROUNDTABLE DISCUSSIONS: MULTIPLE MYELOMA — 1616 Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients
ASH 2021 ROUNDTABLE DISCUSSIONS: MULTIPLE MYELOMA — 1616...
ASH 2021 ROUNDTABLE DISCUSSIONS: MULTIPLE MYELOMA — 2701 The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice
ASH 2021 ROUNDTABLE DISCUSSIONS: MULTIPLE MYELOMA — 2701...
ASH 2021 ROUNDTABLE DISCUSSIONS: MULTIPLE MYELOMA — 3793 Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study
ASH 2021 ROUNDTABLE DISCUSSIONS: MULTIPLE MYELOMA — 3793...
ASH 2021 ROUNDTABLE DISCUSSIONS: MULTIPLE MYELOMA — 817 Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
ASH 2021 ROUNDTABLE DISCUSSIONS: MULTIPLE MYELOMA — 817...
ASH 2021 ROUNDTABLE DISCUSSIONS: MULTIPLE MYELOMA — 2705 Treatment Patterns and Outcomes of Patients with Double-Class Refractory or Triple-Class Refractory Multiple Myeloma: A Retrospective US Electronic Health Record Database Study
ASH 2021 ROUNDTABLE DISCUSSIONS: MULTIPLE MYELOMA — 2705...
ASH 2021 ROUNDTABLE DISCUSSIONS: MULTIPLE MYELOMA — 1644 Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience
ASH 2021 ROUNDTABLE DISCUSSIONS: MULTIPLE MYELOMA — 1644...
GU CANCERS 2022 ROUNDTABLE DISCUSSION
GU CANCERS 2022 ROUNDTABLE DISCUSSIONLearning Objectives:...
GU CANCERS 2022 ROUNDTABLE DISCUSSION: PROSTATE CANCER discussing – PROpel, MAGNITUDE, ARASENS, TITAN
Learning Objectives: GU CANCERS 2022 ROUNDTABLE...
GU CANCERS 2022 ROUNDTABLE DISCUSSION: BLADDER CANCER discussing – TROPHY-U-01 Cohort 3, EV-103 Cohort H and Final Results of Multicenter Prospective Phase II Clinical trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in patients with high grade upper tract urothelial carcinoma.
Learning Objectives: GU CANCERS 2022 ROUNDTABLE...
GU CANCERS 2022 ROUNDTABLE DISCUSSION: RENAL CELL CARCINOMA discussing – Keynote-564
Learning Objectives: GU CANCERS 2022 ROUNDTABLE...
GU CANCERS 2022 ROUNDTABLE DISCUSSION: OTHER ABSTRACTS discussing – The ADVIUVO Study and the Clinical Results of PERICLES.
Learning Objectives: GU CANCERS 2022 ROUNDTABLE...
16th Canadian Melanoma Conference 2022
16th Canadian Melanoma Conference 2022Learning Objectives:...
16th Canadian Melanoma Conference 2022: Unusual Cases of NMSC Encountered by a Med Oncologist – Dr. David Hogg
16th Canadian Melanoma Conference 2022: Unusual Cases of...
16th Canadian Melanoma Conference 2022: Rare Cutaneous Malignancies – Dr. Marie Michelle Blouin
16th Canadian Melanoma Conference 2022: Rare Cutaneous...
16th Canadian Melanoma Conference 2022: MCC – New Treatment Paradigms – Dr. Paul Nghiem
16th Canadian Melanoma Conference 2022: MCC – New...
16th Canadian Melanoma Conference 2022: MCC – Overview of the Canadian Landscape – Dr. Carolyn Nessim
16th Canadian Melanoma Conference 2022: MCC – Overview of...
16th Canadian Melanoma Conference 2022: Sanofi Symposium: Optimizing MDT pathways in the re-defined treatment landscape in skin cancer – Chaired by Dr. Michael Smylie, with Dr. Robyn Macfarlane, Dr. Ian Poon, Dr. Alex Mlynarek, & Dr. Joël Claveau
16th Canadian Melanoma Conference 2022: Sanofi Symposium:...
16th Canadian Melanoma Conference 2022: Systemic Therapy – Dr. Marcus Butler
16th Canadian Melanoma Conference 2022: Systemic...
16th Canadian Melanoma Conference 2022: Liver Directed Therapy – Dr. Marlana Orloff
16th Canadian Melanoma Conference 2022: Liver Directed...
16th Canadian Melanoma Conference 2022: Ocular Oncology Management and Stratified Surveillance – Dr. Ezekiel Weis
16th Canadian Melanoma Conference 2022: Ocular Oncology...
16th Canadian Melanoma Conference 2022: BMS Symposium: Real World Evidence in Melanoma – Does it fill the gap for clinical trials? – Dr. Scott Ernst, Dr. Winson Cheung & Dr. Timothy Hanna
16th Canadian Melanoma Conference 2022: BMS Symposium:...
16th Canadian Melanoma Conference 2022: Clinicopathology Conference: Cases from around Canada – Dr. Scott Ernst, Dr. Joël Claveau & Dr. Louis-Philippe Gagnon
16th Canadian Melanoma Conference 2022: Clinicopathology...
16th Canadian Melanoma Conference 2022: The Role of Genetic/Genomic Testing in Melanoma – Dr. Julia Newton-Bishop
16th Canadian Melanoma Conference 2022: The Role of...
16th Canadian Melanoma Conference 2022: Precision Prevention of Melanoma: The Australian Experience – Prof. Peter Soyer
16th Canadian Melanoma Conference 2022: Precision...
16th Canadian Melanoma Conference 2022: Management of skin toxicity from immunotherapy – Dr. Mario Lacouture
16th Canadian Melanoma Conference 2022: Management of skin...
16th Canadian Melanoma Conference 2022: Pfizer Symposium: Optimizing Targeted Therapy Treatment in BRAF-mutant Metastatic Melanoma – Chaired by Dr. Vanessa Bernstein, with Dr. Hussein Tawbi and Dr. Caroline Robert
16th Canadian Melanoma Conference 2022: Pfizer Symposium:...
16th Canadian Melanoma Conference 2022: Complete Lymph Node Dissection – Dr. Carman Giacomantonio
16th Canadian Melanoma Conference 2022: Complete Lymph...
16th Canadian Melanoma Conference 2022: End Points for Neoadjuvant Trials – Dr. Hussein Tawbi
16th Canadian Melanoma Conference 2022: End Points for...
16th Canadian Melanoma Conference 2022: Is Neoadjuvant Ready for Prime Time – Dr. Vernon Sondak
16th Canadian Melanoma Conference 2022: Is Neoadjuvant...
16th Canadian Melanoma Conference 2022: Merck Breakfast Symposium: Paradigm Shift in Adjuvant Melanoma – A New Frontier in Adjuvant Therapy: Improving care for patients with high-risk disease – Chaired by Dr. Teresa Petrella, with Dr. Jason Luke with panelist, Dr. Joël Claveau
16th Canadian Melanoma Conference 2022: Merck Breakfast...
Best of SABCS® 2022
Best of SABCS® 2022Key Content Areas Include: Describe key...
Best of SABCS® 2022: Gilead Symposium: The evolution of treatment approaches in mTNBC – Dr. Sandy Sedhev & Dr. John Hilton
Best of SABCS® 2022: Gilead Symposium: The evolution of...
Best of SABCS® 2022: Early ER Positive Breast Cancer (Neoadjuvant) – Dr. Bindi Dhesy
Best of SABCS® 2022: Early ER Positive Breast Cancer...
Best of SABCS® 2022: Metastatic ER Positive – Dr. Brooke Wilson
Best of SABCS® 2022: Metastatic ER PositiveKey Content...
Best of SABCS® 2022: Surgical Updates – Dr. Jean-Francois Boileau
Best of SABCS® 2022: Surgical UpdatesKey Content Areas...
Best of SABCS® 2022: Radiation Updates – Dr. David Voduc
Best of SABCS® 2022: Radiation UpdatesKey Content Areas...
Best of SABCS® 2022: Pathology (Biomarkers) Updates – Dr. Brandon Sheffield
Best of SABCS® 2022: Pathology (Biomarkers) UpdatesKey...
Best of SABCS® 2022: Seagen Symposium: A Rapidly Changing HER2+ MBC Landscape: How To Best Sequence Treatment Options for HER2+ MBC Patients – Dr. Karen Gelmon & Dr. Sonal Gandhi
Best of SABCS® 2022: Seagen Symposium: A Rapidly Changing...
Best of SABCS® 2022: Neoadjuvant /Adjuvant Triple Negative Breast Cancer – Dr. Danny Rayson
Best of SABCS® 2022: Neoadjuvant /Adjuvant Triple Negative...
Best of SABCS® 2022: Metastatic Triple Negative Breast Cancer – Dr. Sara Soldera
Best of SABCS® 2022: Metastatic Triple Negative Breast...
Best of SABCS® 2022: Early HER2 Positive Breast Cancer – Dr. Jan-Willem Henning
Best of SABCS® 2022: Early HER2 Positive Breast CancerKey...
Best of SABCS® 2022: Metastatic HER2 Positive Breast Cancer – Dr. Phil Bedard
Best of SABCS® 2022: Metastatic HER2 Positive Breast...
Best of SABCS® 2022: Novel Therapeutics in Breast Cancer – What’s in the Pipeline Development? – Dr. Stephen Chia
Best of SABCS® 2022: Novel Therapeutics in Breast Cancer -...
Best of SABCS UK: 2022
Best of SABCS UK: 2022Learning Objectives: Describe key...
BEST OF SABCS UK: 2022 HER2 Positive Breast Cancer – Dr. Alicia Okines
Learning Objectives: BEST OF SABCS UK: 2022 HER2 Positive...
BEST OF SABCS UK: 2022 Hormone Receptor Positive Breast Cancer – Dr. Anne Armstrong
Learning Objectives: BEST OF SABCS UK: 2022 Hormone...
BEST OF SABCS UK: 2022 Triple Negative Breast Cancer – Prof. Peter Schmid
Learning Objectives: BEST OF SABCS UK: 2022 Triple...
Webinar1: Highlights from SABCS® 2021
Webinar1: Highlights from SABCS® 2021Key Content Areas...
Webinar 2: Triple -ve and HER2+ve Breast Cancer
Webinar 2: Triple -ve and HER2+ve Breast CancerKey Content...
Webinar 3: Hormone+ve Breast Cancer and Breast Cancer Survivorship
Webinar 3: Hormone+ve Breast Cancer and Breast Cancer...
Webinar 4:Australian analysis of SABCS® ‘Year in Review’
Webinar 4:Australian analysis of SABCS® ‘Year in...
GI CANCERS 2022 ROUNDTABLE DISCUSSION
GI CANCERS 2022 ROUNDTABLE DISCUSSIONLearning Objectives:...
GI CANCERS 2022 ROUNDTABLE DISCUSSION: Colorectal discussing Neoadjuvant Dostarlimab for dMMR Rectal Cancer, RESPECT JGOG 1018, ACCENT/IDEA Pooled Analysis of Early Treatment Discontinuation
Learning Objectives: GI CANCERS 2022 ROUNDTABLE...
GI CANCERS 2022 ROUNDTABLE DISCUSSION: Non-Colorectal discussing TOPAZ, HIMALAYA, LAUNCH, CHECKMATE 649 Update, NEONIPIGA
Learning Objectives: GI CANCERS 2022 ROUNDTABLE...
ASH 2021 ROUNDTABLE DISCUSSIONS
Key Content Areas Include: ASH 2021 ROUNDTABLE...
ASH 2021 ROUNDTABLE DISCUSSIONS: LEUKEMIA
Key Content Areas Include: ASH 2021 ROUNDTABLE...
ASH 2021 ROUNDTABLE DISCUSSIONS: LYMPHOMA
Key Content Areas Include: ASH 2021 ROUNDTABLE...
ASH 2021 ROUNDTABLE DISCUSSIONS: LYMPHOMA — Profiling in Patients with CNS Lymphoma
Key Content Areas Include: ASH 2021 ROUNDTABLE...
ASH 2021 ROUNDTABLE DISCUSSIONS: LYMPHOMA — Abstract 523: Initial Results from Alliance A051701
Key Content Areas Include: ASH 2021 ROUNDTABLE...
ASH 2021 ROUNDTABLE DISCUSSIONS: LYMPHOMA — Abstract 379: Results of the MCL R2 Elderly Clinical Trial
Key Content Areas Include: ASH 2021 ROUNDTABLE...
ASH 2021 ROUNDTABLE DISCUSSIONS: LYMPHOMA — CAR T Cell Therapy: Abstract 91 + Analysis of Belinda Study and ZUMA 7
Key Content Areas Include: ASH 2021 ROUNDTABLE...
ASH 2021 ROUNDTABLE DISCUSSIONS: LYMPHOMA — The POLARIX Study
Key Content Areas Include: ASH 2021 ROUNDTABLE...
ASH 2021 ROUNDTABLE DISCUSSIONS: LEUKEMIA—Abstract 70: 1L Treatment of CLL in Elderly or Unfit Patients: The GLOW Study
Key Content Areas Include: ASH 2021 ROUNDTABLE...
ASH 2021 ROUNDTABLE DISCUSSIONS: LEUKEMIA—Abstract 642: Results of the Phase 3 NCRI FLAIR Trial
Key Content Areas Include: ASH 2021 ROUNDTABLE...
ASH 2021 ROUNDTABLE DISCUSSIONS: LEUKEMIA—Abstract 396: SEQUOIA (CLL/SLL)
Key Content Areas Include: ASH 2021 ROUNDTABLE...
ASH 2021 ROUNDTABLE DISCUSSIONS: LEUKEMIA—Abstract 71: Analysis of GAIA (CLL 13) Trial
Key Content Areas Include: ASH 2021 ROUNDTABLE...
ASH 2021 ROUNDTABLE DISCUSSIONS: LEUKEMIA—Abstract 695: FLT3 – Mutated Acute Myeloid Leukemia
Key Content Areas Include: ASH 2021 ROUNDTABLE...
ASH 2021 ROUNDTABLE DISCUSSIONS: LEUKEMIA—Abstract 32+795: CPX-351 – Initial Therapy in Acute Myeloid Leukemia
Key Content Areas Include: ASH 2021 ROUNDTABLE...
ASH 2021 ROUNDTABLE DISCUSSIONS: LEUKEMIA—Abstract 871: Updated Results from QUAZAR AML – 001 Trial
Key Content Areas Include: ASH 2021 ROUNDTABLE...
BEST OF HEMATOLOGY 2022
BEST OF HEMATOLOGY 2022Key Content Areas Include: LEARNING...
BEST OF HEMATOLOGY 2022: Seagen Lunch Symposium: Recent Advances in Newly Diagnosed Advanced Hodgkin’s Lymphoma:Adopting into Clinical Practice – Dr. Andrew Evens & Dr. Kelly Davison
BEST OF HEMATOLOGY 2022: Seagen Lunch Symposium: Recent...
BEST OF HEMATOLOGY 2022: Stem Cell Transplant Update – Dr. Kylie Lepic
BEST OF HEMATOLOGY 2022: Stem Cell Transplant UpdateKey...
BEST OF HEMATOLOGY 2022: Sickle Cell Disease – Dr. Kevin Kuo
BEST OF HEMATOLOGY 2022: Sickle Cell DiseaseKey Content...
BEST OF HEMATOLOGY 2022: Pfizer Symposium: ALL – Dr. Julie Bergeron
BEST OF HEMATOLOGY 2022: Pfizer Symposium: ALLKey Content...
BEST OF HEMATOLOGY 2022: COVID-19 Management (Pre-Hospitalized Heme Onc Patient) – Dr. Menaka Pai
BEST OF HEMATOLOGY 2022: COVID-19 Management...
BEST OF HEMATOLOGY 2022: Evidence informed management of the hospitalized patient with COVID-19 – Dr. Ryan Zarychanski & Dr. Brett Houston
BEST OF HEMATOLOGY 2022: Evidence informed management of...
BEST OF HEMATOLOGY 2022: MPN/MDS – Dr. James Kennedy
BEST OF HEMATOLOGY 2022: MPN/MDSLearning Objectives: Chair...
BEST OF HEMATOLOGY 2022: Myeloma – Dr. Irwin Sandhu
BEST OF HEMATOLOGY 2022: MyelomaKey Content Areas Include:...
BEST OF HEMATOLOGY 2022: Aggressive Lymphoma – Dr. Anca Prica
BEST OF HEMATOLOGY 2022: Aggressive LymphomaKey Content...
BEST OF HEMATOLOGY 2022: Janssen Breakfast Symposium: Maximizing Long-Term Outcomes in CLL – Dr. Versha Banerji
BEST OF HEMATOLOGY 2022: Janssen Breakfast Symposium:...
ESMO 2021 Roundtable: Lung Cancer
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: LUNG HER2-mutated (HER2m) Metastatic NSCLC / NSCLC Harboring HER2 Exon 20 Mutations
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: LBA9 – IMpower010: Sites of Relapse and Subsequent Therapy from a Phase III Study of Atezolizumab vs Best Supportive Care After Adjuvant Chemotherapy in Stage IB-IIIA NSCLC
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: EGFR-mutant NSCLC-Beverley LBA 44
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: EGFR-mutant NSCLC-Chrysallis 1 and 2
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: LBA43 Unresectable Stage III NSCLC
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: First Line (1L) Treatement of Advanced NSCLC
Key Content Areas Include: This program has been made...
ESMO 2021 Roundtable: Precision Oncology
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: Prediction of Distant Relapse in Patients with Invasive Breast Cancer from Deep Learning Models Applied to Digital Pathology Slides
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: HER2+ Metastatic Breast Cancer
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: Patients (pts) with First-line (1L) Advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST)
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: Stage IIIB-D Melanoma Patients (pts) Stratified According to the Interferon-gamma Signature (IFN-γ sign)
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: Patients with Metastatic or Locally Advanced Urothelial Carcinoma (mUC) and Fibroblast Growth Factor Receptor Alterations (FGFRa)
Key Content Areas Include: This program has been made...
ESMO 2021 Roundtable: GU
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: Prostate: ARCHES, VISION
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: Prostate: STAMPEDE
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: Prostate: PEACE 1
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: Bladder Cancer: Bladder NORSE, 6510
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: Renal Cell Carcinoma:STAR, BONSAI,
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: Bladder:VESPER
Key Content Areas Include: This program has been made...
SABCS 2021 ROUNDTABLE DISCUSSION
SABCS 2021 ROUNDTABLE DISCUSSIONKey Content Areas Include:...
SABCS 2021 ROUNDTABLE DISCUSSION: Triple Negative Breast Cancer
SABCS 2021 ROUNDTABLE DISCUSSION: Triple Negative Breast...
SABCS 2021 ROUNDTABLE DISCUSSION: HER-2+ Breast Cancer
SABCS 2021 ROUNDTABLE DISCUSSION: HER-2+ Breast CancerKey...
SABCS 2021 ROUNDTABLE DISCUSSION: HR+ Breast Cancer
SABCS 2021 ROUNDTABLE DISCUSSION: HR+ Breast CancerKey...
ESMO 2021 ROUNDTABLE: GI Cancer
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: GI Gastrointestinal Cancer—Pancreatic: PRODIGE24
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: GI Gastrointestinal Cancer— Gastroesophageal: CHECKMATE, ORIENT, JUPITER
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: GI Gastrointestinal Cancer—Colorectal: FOCUS4
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: GI Gastrointestinal Cancer—Colorectal: MAYA
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: GI Gastrointestinal Cancer—Colorectal: AtezoTRIBE
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: GI Gastrointestinal Cancer—Colorectal: KRYSTAL
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: GI Gastrointestinal Cancer—Biliary Tract: NIFE
Key Content Areas Include: This program has been made...
ESMO 2021 Roundtable – Breast
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE:(HR+/HER2−) Advanced Breast Cancer (ABC) Treated with Endocrine Therapy
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: HER2+ Metastatic Breast Cancer
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: Pre-treated HER2-positive Locally Advanced or Metastatic Breast Cancer
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: Metastatic Triple-negative Breast Cancer
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: Keynote: Breast Neoadjuvant Chemotherapy in TNBC
Key Content Areas Include: This program has been made...
ESMO 2021 ROUNDTABLE: Breast Neoadjuvant Chemotherapy in TNBC
Key Content Areas Include: This program has been made...
Best of Oncology West 2022
Key Content Areas Include: LEARNING OBJECTIVES: 1. To...
BEST OF ONCOLOGY WEST: 2022 Breast Cancer – Dr. Nancy Nixon
BEST OF ONCOLOGY WEST: 2022 Breast CancerKey Content Areas...
BEST OF ONCOLOGY WEST: 2022 Melanoma – Dr. Alison Weppler
BEST OF ONCOLOGY WEST: 2022 MelanomaKey Content Areas...
BEST OF ONCOLOGY WEST: 2022 Lymphoma – Dr. Kerry Savage
BEST OF ONCOLOGY WEST: 2022 LymphomaKey Content Areas...
BEST OF ONCOLOGY WEST: 2022 Non-Colorectal GI Cancer – Dr. Hatim Karachiwala
BEST OF ONCOLOGY WEST: 2022 Non-Colorectal GI CancerKey...
BEST OF ONCOLOGY WEST: 2022 Colorectal GI Cancer – Dr. Sharlene Gill
BEST OF ONCOLOGY WEST: 2022 Colorectal GI CancerKey...
BEST OF ONCOLOGY WEST: 2022 Thrombosis in Cancer – Dr. Agnes Lee
BEST OF ONCOLOGY WEST: 2022 Thrombosis in CancerKey...
BEST OF ONCOLOGY WEST: 2022 Lung Cancer – Dr. Aliyah Pabani
BEST OF ONCOLOGY WEST: 2022 Lung CancerKey Content Areas...
BEST OF ONCOLOGY WEST: 2022 Head & Neck – Dr. Nicole Chau
BEST OF ONCOLOGY WEST: 2022 Head & NeckKey Content...
BEST OF ONCOLOGY WEST: 2022 Gynecological Cancers – Dr. Yvette Drew
Key Content Areas Include: BEST OF ONCOLOGY WEST: 2022...
BEST OF ONCOLOGY WEST: 2022 Non-Prostate GU Cancer – Dr. Lucia Nappi
BEST OF ONCOLOGY WEST: 2022 Non-Prostate GU CancerKey...
BEST OF ONCOLOGY WEST: 2022 Prostate GU Cancer – Dr. Steven Yip
BEST OF ONCOLOGY WEST: 2022 Prostate GU CancerKey Content...
BEST OF ONCOLOGY WEST: 2022 Molecular Genetics Testing 101 – Dr. Alexander Wyatt
BEST OF ONCOLOGY WEST: 2022 Molecular Genetics Testing...
Best of Oncology East 2021: Breast Cancer – Dr. Mark Clemons
Best of Oncology East 2021: Breast CancerChair Dr. Scott...
Best of Oncology East 2021: Non-Prostate GU Cancer – Dr. Aly-Khan Lalani
Best of Oncology East 2021: Non-Prostate GU CancerChair...
Best of Oncology East 2021: Prostate Cancer – Dr. Sebastien Hotte
Best of Oncology East 2021: Prostate Cancer Chair Dr....
Best of Oncology East 2021: BMS Lunch Symposia: IO Treatment for RCC: How we got to where we are – Dr. Christian Kollmannsberger with Dr. Aly-Khan Lalani
Best of Oncology East 2021: BMS Lunch Symposia: IO...
Best of Oncology East 2021: Pancreatic, Biliary, and HCC – Dr. Ravi Ramjeesingh
Best of Oncology East 2021: Pancreatic, Biliary, and...
Best of Oncology East 2021: Gastroesophageal Cancer – Dr. Elena Elimova
Best of Oncology East 2021: Gastroesophageal CancerChair...
Best of Oncology East 2021: Colorectal Gl Cancer – Dr. Rachel Goodwin
Best of Oncology East 2021: Colorectal Gl CancerChair Dr....
Best of Oncology East 2021: What Medical Oncologists need to know about New Molecular Diagnostics – Dr. Brandon Sheffield
Best of Oncology East 2021: What Medical Oncologists need...
Best of Oncology East 2021: Lung Cancer – Dr. Jeff Rothenstein
Best of Oncology East 2021: Lung CancerChair Dr. Scott...
Best of Oncology East 2021: AZ Breakfast Symposia: Targeted therapies in 2021- Managing Early and Late Stage EGFR + NSCLC- Dr. Parneet Cheema with Dr. Diana Ionescu
Best of Oncology East 2021: AZ Breakfast Symposia:...
Best of Lung Cancer Summit 2021
Key Content Areas Include: Lorem ipsum dolor sit amet,...
Best of Precision Oncology 2021
Best of Precision Oncology 2021Learning Objectives:...
Best of Precision Oncology 2021: Future Look at Emerging Technology and Targets in Oncology – Prof. Tony Mok
Best of Precision Oncology 2021: Future Look at Emerging...
Best of Precision Oncology 2021: Debate: Be it resolved that precision therapies should only be adopted based on the results of randomized Phase 3 Trials – Dr. Jack West vs. Dr. Christian Rolfo
Best of Precision Oncology 2021: Debate: Be it resolved...
Best of Precision Oncology 2021: Pfizer Lunch Symposium: Access to Biomarker Testing in Canada: Clinician and Patient Viewpoints – Dr. Rachel Goodwin with Dr. Brandon Sheffield & Barry Stein
Best of Precision Oncology 2021: Pfizer Lunch Symposium:...
Best of Precision Oncology 2021: Breakout: GI – Dr. Daniel Renouf with Prof. Elizabeth Symth
Best of Precision Oncology 2021: Breakout: GILearning...
Best of Precision Oncology 2021: Breakout: GU – Prof. Tom Powles with Dr. Daniel Heng
Best of Precision Oncology 2021: Breakout: GULearning...
Best of Precision Oncology 2021: Breakout: Melanoma – Prof. Teresa Amaral with Dr. John Haanen
Best of Precision Oncology 2021: Breakout:...
Best of Precision Oncology 2021: Breakout: Breast Cancer – Prof. Matteo Lambertini with Prof. Samreen Ahmed
Best of Precision Oncology 2021: Breakout: Breast...
Best of Precision Oncology 2021: Breakout: Lung Cancer – Dr. Roy Herbst with Dr. Natasha Leighl
Best of Precision Oncology 2021: Breakout: Lung...
Best of Precision Oncology 2021: Breakout: Hematology – Dr. Aaron Schimmer with Prof. Gabriela Baerlocher
Best of Precision Oncology 2021: Breakout:...
Best of Precision Oncology 2021: Tumour Agnostic Biomarker Driven Therapy – Dr. Barbara Melosky
Best of Precision Oncology 2021: Tumour Agnostic Biomarker...
Best of Precision Oncology 2021: Molecular Testing: What practicing clinicians need to know – Dr. Ming Tsao
Best of Precision Oncology 2021: Molecular Testing: What...
Best of Precision Oncology 2021: Eli Lily Breakfast Symposium: Assessing RET-Altered Tumors: An increasingly important target for precision oncology- Dr. Alex Drilon with panelist, Dr. Diana Ionescu
Best of Precision Oncology 2021: Eli Lily Breakfast...
Canadian Immuno-Oncology Summit 2021 – Podcasts
Learning Objectives Lorem ipsum dolor sit amet,...
New Drug Development & Biomarkers – Dr. Anna Spreafico
Learning Objectives New Drug Development & Biomarkers...
GI – Colorectal and Non-Colorectal – Dr. Sharlene Gill
Learning Objectives GI - Colorectal and Non-Colorectal -...
Microbiota – Dr. Karen Madsen
Learning Objectives Microbiota - Dr. Karen Madsen
Rheumatologic Toxicities – Dr. Carrie Ye
Learning Objectives Rheumatologic Toxicities - Dr. Carrie Ye
Breast Cancer – Dr. Stephen Chia
Learning Objectives Breast Cancer - Dr. Stephen Chia
Lung Cancer – Dr. Rosalyn Juergens
Learning Objectives Lung Cancer - Dr. Rosalyn Juergens
Symposium: Utility of Combination Therapy in Oncology – Dr. Sebastien Hotte
Learning Objectives Symposium: Utility of Combination...
Head & Neck – Dr. Marco Iafolla
Learning Objectives Head & Neck - Dr. Marco Iafolla
CAR T-Cell Therapy – Dr. Michael Chu
Learning ObjectivesCAR T-Cell Therapy - Dr. Michael Chu
Melanoma – Dr. Omid Hamid
Learning ObjectivesMelanoma - Dr. Omid Hamid
Keynote Lecture: Drug Development in Immuno – Oncology – Dr. Jason Luke
Learning Objectives Keynote Lecture: Drug Development in...
Best of Lung Cancer Summit 2021: Eli Lilly Breakfast Symposium: Recent Advances un RET-Altered NSCLC – Dr. Adrian Sacher with panelist, Dr. Brandon Sheffield
Best of Lung Cancer Summit 2021: Eli Lilly Breakfast...
Best of Lung Cancer Summit 2021: Radiation for Small Cell – Dr. Mitchell Liu
Best of Lung Cancer Summit 2021: Radiation for Small...
Best of Lung Cancer Summit 2021: Post-Surgery Treatment – Dr. Stephanie Snow
Best of Lung Cancer Summit 2021: Post-Surgery TreatmentKey...
Best of Lung Cancer Summit 2021: Surgery for Small Cell – Dr. Donna Maziak
Best of Lung Cancer Summit 2021: Surgery for Small CellKey...
Best of Lung Cancer Summit 2021: Amgen Lunch Symposium: The race to target KRAS: Old Target in New Patients – Dr. Normand Blais
Best of Lung Cancer Summit 2021: Amgen Lunch Symposium:...
Best of Lung Cancer Summit 2021: Debate: Adjuvant Therapy – Is DFS a satisfactory end point? – Dr. David Stewart vs. Dr. Shantanu Banerji
Best of Lung Cancer Summit 2021: Debate: Adjuvant Therapy...
Best of Lung Cancer Summit 2021: Debate: Adjuvant vs. Neoadjuvant Treatment – Dr. Jonathan Spicer vs. Dr. Catherine Labbé
Best of Lung Cancer Summit 2021: Debate: Adjuvant vs....
Best of Lung Cancer Summit 2021: National Screening Update – Ms. Erika Nicholson
Best of Lung Cancer Summit 2021: National Screening...
Best of Lung Cancer Summit 2021: Lung Cancer Screening for Never Smokers – Dr. Renelle Myers
Best of Lung Cancer Summit 2021: Lung Cancer Screening for...
Best of Lung Cancer Summit 2021: Systemic Small Cell – Dr. Kevin Jao
Best of Lung Cancer Summit 2021: Systemic Small CellKey...
Real-World Evidence and the Patient Journey: What Does the Future Hold?
Learning Objectives: To understand the current landscape...
MRD Assessment in Adult ALL…Why and How?
Learning Objectives to appreciate the importance of MRD...
Maximizing Patient Outcomes in Adult Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Learning Objectives Discuss strategies to give patients...
Maximizing Outcomes in Relapsed Multiple Myeloma / Maximiser les résultats dans le myélome multiple récidivant
Learning Objectives L'attrition des patients dans toutes...
The Critical Role of MRD Testing in Acute Lymphoblastic Leukemia
Learning objetives Discuss the benefits of MRD testing...
Moving towards personalized approaches in multiple myeloma
Learning objetives Discuss strategies for tailoring care...
Multiple Myeloma: Treatment at first relapse
Learning objectives Review updated clinical data on...